CN101648008B - 用于关节保健的复合制剂及其制备方法 - Google Patents
用于关节保健的复合制剂及其制备方法 Download PDFInfo
- Publication number
- CN101648008B CN101648008B CN 200910169810 CN200910169810A CN101648008B CN 101648008 B CN101648008 B CN 101648008B CN 200910169810 CN200910169810 CN 200910169810 CN 200910169810 A CN200910169810 A CN 200910169810A CN 101648008 B CN101648008 B CN 101648008B
- Authority
- CN
- China
- Prior art keywords
- glucosamine
- joint
- preparation
- agent
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 title claims abstract description 12
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 23
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 22
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 20
- 108010035532 Collagen Proteins 0.000 claims abstract description 20
- 102000008186 Collagen Human genes 0.000 claims abstract description 20
- 229960002442 glucosamine Drugs 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 17
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 14
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 10
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 239000011230 binding agent Substances 0.000 claims description 13
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 206010003246 arthritis Diseases 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 239000000080 wetting agent Substances 0.000 abstract description 5
- 229920001436 collagen Polymers 0.000 abstract description 4
- 229910019142 PO4 Inorganic materials 0.000 abstract description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 3
- 239000010452 phosphate Substances 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000007884 disintegrant Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 3
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 abstract 2
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical group NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 229960001911 glucosamine hydrochloride Drugs 0.000 abstract 2
- 229960002849 glucosamine sulfate Drugs 0.000 abstract 2
- 206010060820 Joint injury Diseases 0.000 abstract 1
- 239000007767 bonding agent Substances 0.000 abstract 1
- 230000029087 digestion Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 10
- 210000000845 cartilage Anatomy 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 210000001188 articular cartilage Anatomy 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 102000016611 Proteoglycans Human genes 0.000 description 6
- 108010067787 Proteoglycans Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- -1 hydroxypropyl Chemical group 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002301 glucosamine derivatives Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 125000001741 organic sulfur group Chemical group 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical group OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000004263 amino monosaccharides Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910169810 CN101648008B (zh) | 2009-09-04 | 2009-09-04 | 用于关节保健的复合制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910169810 CN101648008B (zh) | 2009-09-04 | 2009-09-04 | 用于关节保健的复合制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101648008A CN101648008A (zh) | 2010-02-17 |
CN101648008B true CN101648008B (zh) | 2012-06-06 |
Family
ID=41670406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910169810 Active CN101648008B (zh) | 2009-09-04 | 2009-09-04 | 用于关节保健的复合制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101648008B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101822684B (zh) * | 2010-05-27 | 2012-08-15 | 江苏江山制药有限公司 | 用于防治骨关节痛的复方组合制剂及其制备方法 |
CN101829125B (zh) * | 2010-05-27 | 2012-07-18 | 江苏江山制药有限公司 | 用于防治骨关节痛的复方组合制剂及其制备方法 |
CN102600458A (zh) * | 2011-11-01 | 2012-07-25 | 江苏江山制药有限公司 | 一种氨糖软骨素的复方制剂及其制作方法 |
CN102423487B (zh) * | 2011-12-23 | 2014-04-16 | 内蒙古伊利实业集团股份有限公司 | 一种骨关节保健组合物及其应用 |
CN103356700B (zh) * | 2012-03-26 | 2014-10-29 | 朱晓明 | 关节养护膏 |
CN103239705B (zh) * | 2013-05-10 | 2015-07-15 | 汪华东 | 一种鳄鱼胶原蛋白抗菌肽的组合物及其制备方法 |
CN104621432A (zh) * | 2013-11-12 | 2015-05-20 | 江苏艾兰得营养品有限公司 | 一种氨基葡萄糖复合片及其制备方法 |
CN104873534A (zh) * | 2015-04-03 | 2015-09-02 | 广东先强药业有限公司 | 一种氨基葡萄糖软骨素片及其制备工艺 |
CN106072651B (zh) * | 2016-07-19 | 2019-08-23 | 山东明仁福瑞达制药股份有限公司 | 一种具有增加骨密度、抗炎镇痛作用的组合物及其制备方法 |
CN111467480A (zh) * | 2020-04-26 | 2020-07-31 | 山东朱氏药业集团有限公司 | 一种氨基葡萄糖硫酸软骨素加钙片及制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1439313A (zh) * | 2003-04-02 | 2003-09-03 | 李安虎 | 一种关节保健饮品或食品及其制备方法 |
CN101248882A (zh) * | 2008-03-28 | 2008-08-27 | 北京东方兴企食品工业技术有限公司 | 一种具有促进骨骼和骨关节健康的营养食品 |
-
2009
- 2009-09-04 CN CN 200910169810 patent/CN101648008B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1439313A (zh) * | 2003-04-02 | 2003-09-03 | 李安虎 | 一种关节保健饮品或食品及其制备方法 |
CN101248882A (zh) * | 2008-03-28 | 2008-08-27 | 北京东方兴企食品工业技术有限公司 | 一种具有促进骨骼和骨关节健康的营养食品 |
Also Published As
Publication number | Publication date |
---|---|
CN101648008A (zh) | 2010-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101648008B (zh) | 用于关节保健的复合制剂及其制备方法 | |
CN101829125B (zh) | 用于防治骨关节痛的复方组合制剂及其制备方法 | |
US10149822B2 (en) | Compositions and methods for combination ingredient delivery | |
CN101653451B (zh) | 用于关节保健和增加骨密度的保健品及其制备方法 | |
CN102526058A (zh) | 一种含氯诺昔康和埃索美拉唑消炎镇痛药物组合物 | |
CN101888834A (zh) | 口服分散片 | |
CN101647805B (zh) | 用于缓解和预防骨关节炎的氨基葡萄糖咀嚼片及制备方法 | |
CN101822684B (zh) | 用于防治骨关节痛的复方组合制剂及其制备方法 | |
CN104621432A (zh) | 一种氨基葡萄糖复合片及其制备方法 | |
KR20090089867A (ko) | 간독성 감소를 비롯한 부작용을 최소화한 아세트아미노펜 조성물 | |
CN102600458A (zh) | 一种氨糖软骨素的复方制剂及其制作方法 | |
CN1947724A (zh) | 复方盐酸氨基葡萄糖硫酸软骨素泡腾片及其制备方法、用途 | |
CN116726141A (zh) | 预防和缓解骨关节病的组合物及其应用 | |
CN103768530A (zh) | 一种治疗骨关节病变的药物组合物及其制备方法和用途 | |
CN109453169B (zh) | 草乌甲素的用途 | |
CN101401796A (zh) | 普拉克索口腔崩解片及其制备方法 | |
CN101642442B (zh) | 用于防治骨关节炎的片剂及其制备方法 | |
CN100496515C (zh) | 一种环形泡腾剂型及其制备方法 | |
CN104721805A (zh) | 一种用于缓解和预防关节疾病的颗粒剂及其制备方法 | |
CN101125147B (zh) | 氨基葡萄糖钙的药物制剂、制备方法及其应用 | |
CN101904958A (zh) | 治疗骨折的口服药组合物 | |
CN102961455B (zh) | 一种治疗腰椎间盘突出的中草药粉剂及使用方法 | |
Kamble et al. | Preparation of Tablet from Naagdon Plant by Wet Granulation Method for Treatment of Excessive Bleeding in Piles | |
CN106606491A (zh) | 一种治疗腰椎间盘突出的药用胶原酶泡腾片及其制备方法 | |
CN101176732A (zh) | 一种盐酸氨基葡萄糖分散片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100217 Assignee: Jiangsu Aland Nourishment Co.,Ltd. Assignor: DSM JIANGSHAN PHARMACEUTICAL (JIANGSU) Co.,Ltd. Contract record no.: 2013320000489 Denomination of invention: Compound preparation used for joint care and preparation method thereof Granted publication date: 20120606 License type: Exclusive License Record date: 20130604 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU ALAND NOURISHMENT CO., LTD. Free format text: FORMER OWNER: JIANGSHAN PHARMACEUTICAL CO., LTD., JIANGSU PROV. Effective date: 20131022 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20131022 Address after: 214500, Jiangshan Road, Jiangsu, Jingjiang 20 Patentee after: JIANGSU ALAND NOURISHMENT Co.,Ltd. Address before: 214500, Jiangshan Road, Jiangsu, Jingjiang 20 Patentee before: DSM JIANGSHAN PHARMACEUTICAL (JIANGSU) Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151201 Address after: 214500, 61 Jiangshan Road, Taizhou, Jiangsu, Jingjiang Patentee after: ABRAM (JIANGSU) ANIMAL HEALTH Co.,Ltd. Address before: 214500, Jiangshan Road, Jiangsu, Jingjiang 20 Patentee before: Jiangsu Aland Nourishment Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 18, Jingjiang City, Jiangsu, Taizhou, Jiangsu Patentee after: JIANGSU YABO ANIMAL HEALTH TECHNOLOGY CO.,LTD. Address before: 214500, 61 Jiangshan Road, Taizhou, Jiangsu, Jingjiang Patentee before: ABRAM (JIANGSU) ANIMAL HEALTH Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20230614 Address after: 211199 Room 1809, Building A-1, Lvlizhichuang Business Plaza, Dongshan Street, Jiangning District, Nanjing City, Jiangsu Province Patentee after: Shengjinhe Biotechnology (Jiangsu) Co.,Ltd. Address before: 214500 No.18, Zhifang Road, Jingjiang City, Taizhou City, Jiangsu Province Patentee before: JIANGSU YABO ANIMAL HEALTH TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right |